|
Cannabis Campaigners' Guide News Database result:
|
|
UK: Cannabis Grower Set For Listing on AIM
ccguide Wednesday 16 May 2001 Pubdate: Tue, 15 May 2001 Source: Financial Times (UK) Copyright: The Financial Times Limited 2001 Contact: Website: http://www.ft.com/ Details: http://www.mapinc.org/media/154 Author: Francesco Guerrera Bookmark: http://www.mapinc.org/find?323 (GW Pharmaceuticals) CANNABIS GROWER SET FOR LISTING GW Pharmaceuticals, poised to become the world's first company to derive a medicine from cannabis, is to announce plans for a London listing that could value it at up to Pounds 170m. GW's listing on the Alternative Investment Market will be accompanied by a Pounds 16m institutional placing by its adviser Collins Stewart. The proceeds, and Pounds 5.5m already in the bank, will be used to increase the production of cannabis and fund clinical trials of its drugs. The company grows 15 tonnes of cannabis a year under government licence in a secret location in England to develop drugs against diseases. GW's most advanced product is a drug for multiple sclerosis, which is due to be submitted to the UK medicine watchdog in 2003. If approved, it will become the world's first cannabis-based medicine and is expected to trigger a change in the UK drug laws. An estimated 3,000 MS sufferers already break the law by smoking cannabis to alleviate the symptoms of the disease. GW's product is delivered through a spray. Analysts estimate GW's MS drug could reach maximum sales of Pounds 500m a year. The condition is poorly treated by existing drugs. Geoffrey Guy, GW's executive chairman, said GW had decided to float to raise the funds needed to support its product pipeline and continue strong growth. "Flotation will enable GW to develop into a pharmaceutical company capable of establishing a position in several large markets," he added. GW plans to sell the rights to products to pharmaceutical companies, which would pay for marketing, in exchange for a percentage of sales. Mr Guy, who will own nearly 30 per cent of the company after the listing, founded GW in 1998. Since then it has raised Pounds 12m from individuals and institutional investors, including investment boutique Bradmount Investments. Last year, GW had a cash burn of Pounds 3m, which is expected to double this year as the MS products moves into the last phase of clinical trials. The group is expected to make its first pre-tax profit in the year to September 2004. - --- MAP posted-by: Terry Liittschwager
After you have finished reading this article you can click here to go back.
|
This page was created by the Cannabis Campaigners' Guide.
Feel free to link to this page!